Fourth-Quarter and Full-Year 2019 Orphan and Rheumatology Segment Results
We Have Transformed into a Rare Disease Focused Company through Acquisitions
2014
September 2014
Acquisition of
Vidara
Therapeutics Intl.
ACTIMMUNE™
(Interferon gamma-1b)
HORIZON
RAVICTI
(glycerol phenylbutyrate) Oral Liquid
May 2015
Acquisition of Hyperion
Therapeutics, Inc.
2015
January 2016
Acquisition of Crealta
Holdings LLC
2016
KRYSTEXXA!
pegloticase
12-HOUR
PROCYSBI
(cysteamine bitartrate)
delayed-release capsules
HZN-003 and HZN-007
for uncontrolled gout
October 2016
Acquisition of Raptor
Pharmaceutical Corp.
January 2018
•
Acquisition of HZN-003
from MedImmune LLC
• Partnered with XL-protein
GmbH on HZN-007
(PASylated Uricase)
2016
2017
2018
2019
May 2017
January 2019
Acquisition of River Vision
Development Corp.
Collaboration with HemoShear
Therapeutics LLC
TEPEZZA.M
teprotumumab-trbw
Gout Discovery
Collaboration
38View entire presentation